DOCSLIB.ORG

Biotechnology State of the Industry R E P O R T 2 • 0 • 0

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biotechnology State of the Industry R E P O R T 2 • 0 • 0 BIOWORLD® BIOTECHNOLOGY STATE OF THE INDUSTRY REPORT 2•0•0•6 THE BIOWORLD® STATE OF THE INDUSTRY REPORT 2006 is published by Thomson BioWorld®, 3525 Piedmont Road, Building Six, Suite 400, Atlanta, GA 30305 USA. Opinions expressed are not necessarily those of this publication. Mention of prod- ucts or services does not constitute endorsement. Thomson BioWorld® is a division of Thomson Healthcare. Copyright © 2006 Thomson BioWorld®. All Rights Reserved. No part of this publication may be reproduced without the written consent of Thomson BioWorld®. (GST Registration Number R128870672) Managing Editor: Brady Huggett. Senior Production Editor: Kay Torrance. Database Editor: Jim Shrine. Staff Writers: Karen Pihl-Carey, Jennifer Boggs. Science Editor: Anette Breindl. National Editor: Randall Osborne. Washington Editor: Aaron Lorenzo. Vice President/Group Publisher: Donald R. Johnston. Marketing Manager: Chris Walker. Account Representatives: Bob Sobel, Steve Roberts. Customer Service: (800) 688-2421 or (404) 262-5476. NO PART OF THIS PUBLICATION MAY BE REPRODUCED WITHOUT THE WRITTEN CONSENT OF THOMSON BIOWORLD®. To obtain photocopying rights or subscribe, please call (800) 688-2421. Table Of Contents I. Analysis Biotech Continues Growth In Quieter, Calmer Environment ................................................................................9 The Year In Review....................................................................................................................................................................1 1 The View From Wall Street ..................................................................................................................................................17 The View From Washington................................................................................................................................................22 The View From The Lab Bench..........................................................................................................................................25 II. Financial Data Discerning Market, Caution Drove Trends In Financing ......................................................................................33 Money Raised By Biotechnology Companies ............................................................................................................36 Initial Public Offerings..........................................................................................................................................................37 Follow-On Offerings ............................................................................................................................................................42 After-Market Performance (Initial Public Offerings)................................................................................................49 After-Market Performance (Follow-On Offerings) ....................................................................................................50 Initial Public Offerings: 2002-2005 (Gross Proceeds By Month) ......................................................................53 Follow-On Offerings: 2002-2005 (Gross Proceeds By Month)............................................................................54 Gross Proceeds Of Biotech Public Stock Offerings: By Quarter 1995-2005..................................................55 Miscellaneous Financings Of Public Biotech Companies......................................................................................56 Venture Capital And Other Financings Of Private Biotechnology Firms ........................................................91 Milestones And Equity Investments From Corporate Partners ........................................................................121 Grants And Awards To Biotech Companies ..............................................................................................................134 III. Corporate Deals Major Playor Novartis Pays Big For Products, Platforms......................................................................................165 Biotechnology Mergers And Acquisitions..................................................................................................................169 Biotech-Big Pharma Collaborations: New Agreements ........................................................................................190 Biotech-Big Pharma Collaborations: Modified And Terminated Agreements ..........................................242 Manufacturing, Marketing And Distribution Agreements With Pharma Companies ............................250 Biotech-Biotech Deals: Collaborations, Agreements And Equity Participation ........................................260 Biotech-Biotech Collaborations: Modified And Terminated Agreements ..................................................300 Manufacturing, Marketing And Distribution Agreements Between Biotechnology Companies......302 Biotech Miscellaneous Collaborations........................................................................................................................309 Biotech-University/Nonprofit Institutions Collaborations ................................................................................312 Biotech-Agribusiness Collaborations..........................................................................................................................350 IV. Biotech Product Development Who’s To Blame For Fewer Approvals: FDA Or Biotech?......................................................................................359 Biotechnology Products Approved By FDA In 2005 ............................................................................................363 Biotechnology Products On The Market....................................................................................................................367 FDA Actions On Pending Applications In 2005 ......................................................................................................384 Licensing Applications Filed And Pending At FDA In 2005 ..............................................................................387 Products Not Recommended For Approval By FDA Advisory Panels In 2005..........................................393 Overseas Approvals And Actions In 2005................................................................................................................394 V. Report Card For Wall Street Methodology Used To Evaluate Underwriters’ Performance............................................................................405 Top 10 Underwriters: Full Credit To Lead Underwriters; Ranked By Gross Proceeds ............................406 Other Underwriters: Full Credit To Lead Underwriters; Ranked By Gross Proceeds..............................407 Top 10 Underwriters: Full Credit To All Underwriters; Ranked By Gross Proceeds ................................408 Other Underwriters: Full Credit To All Underwriters; Ranked By Gross Proceeds ..................................409 Top 9 Underwriters: IPOs (Full Credit To Lead Underwriters, Ranked By Gross Proceeds) ..................41 1 Other Underwriters: IPOs (Full Credit To Lead Underwriters, Ranked By Gross Proceeds ..................412 Top 10 Underwriters: IPOs (Full Credit To All Underwriters; Ranked By Gross Proceeds) ....................413 Other Underwriters: IPOs (Full Credit To All Underwriters; Ranked By Gross Proceeds)......................414 Top 9 Underwriters: IPO (Full Credit To Lead Underwriters; Ranked By After-Market Performance)......415 Other Underwriters: IPO (Full Credit To Lead Underwriters; Ranked By After-Market Performance)......416 Top 10 Underwriters: IPO (Full Credit To All Underwriters; Ranked By After-Market Performance) ......417 Other Underwriters: IPO (Full Credit To All Underwriters; Ranked By After-Market Performance)........418 VI. Stock Performance 2005 Stock Report: An Alphabetical Listing Of Public Biotech Companies................................................421 2005 British Stock Report ................................................................................................................................................427 2005 Canadian Stock Report..........................................................................................................................................428 2005 Price Performance: Biotechnology Stocks Ranked By Percent Change For Year..........................429 Tracking The Overall Performance Of The 279 Stocks In BioWorld’s Universe ......................................433 BioWorld Stock Indicator Vs. Nasdaq Biotech Index ............................................................................................435 BIOWORLD® ANALYSIS Biotech Continues Growth In Quieter, Calmer Environment By Brady Huggett Managing Editor In many ways, 2005 looked a lot like 2004. Total money raised last year nearly equaled the year prior, when the industry raised $20.8 billion. There were 33 initial public offerings around the world in 2005, just slightly off from the 37 that completed in 2004. The markets were steady both years – BioWorld’s stock tracker showed the aver- age biotech firm’s shares in 2005 lost just 2 percent, compared to the 2.5 percent gained in 2004. Those signs point to a leveling off for the sector, suggesting that gone are the days of an opening and then abruptly slamming IPO window, gone are collective plummeting and zooming of stock prices, based on a single firm’s news.
Load more

Recommended publications
  • Orpheus Cover Cover Concepts
    (ACN 121 257 412) PROSPECTUS for the offer by Orpheus Energy Limited of up to 50,000,000 Shares at 25 cents each with oversubscriptions of up to a further 10,000,000 Shares including the Rights Issue to existing Shareholders as at the Record Date Lead Manager BBY Limited IMPORTANT NOTICE ASX Code to be OEG. This document is important and should be read in its entirety. If you are in any doubt as to the course you should follow you should consult your stockbroker, solicitor, accountant or other professional adviser. This is a speculative investment.. Corporate Directory Directors Independent Geologist – Indonesia Mr Wayne Douglas Mitchell, Chairman, Ravensgate CEO & Managing Director Level 3, 44 Parliament Place Mr Wesley Harder, Director – Exploration West Perth WA 6005 Mr Anthony Meacham King, Director Independent Geologist – Australia Proposed Directors Minarco-MineConsult Mr Nugroho Suksmanto Level 16, Australia Square Mr Michael Rhodes (alternate director to Nugroho 264-278 George St Suksmanto) Sydney NSW 2000 Company Secretary Auditor Mr Nathan Bartrop Bentleys Melbourne Audit Pty Ltd Level 7 114 William Street Registered Office Melbourne VIC 3000 Level 5, 44 Miller St North Sydney NSW 2060 Independent Accountant Stantons International Securities Share Registry Level 1 Security Transfer Registrars Pty Ltd 1 Havelock Street 770 Canning Highway West Perth WA 6000 Applecross WA 6953 Title Report – Indonesia Lead Manager Hadiputranto, Hadinoto & Partners BBY Limited The Indonesia Stock Exchange Building Level 17, 60 Margaret Street Tower II, 21st Floor Sydney NSW 2000 JI. Jend. Sudirman Kav.52-53 Jakarta 12190 Indonesia Sponsoring Broker Centre Capital Securities Pty Ltd Title Report – Australia 14 Macquarie Street Hetherington Exploration & Belmont NSW 2280 Mining Title Services Pty Limited Level 1, 503 Willoughby Rd Solicitors Willoughby NSW 2068 Whitttens Lawyers and Consultants Level 5 137 Bathurst Street Sydney NSW 2000 i CORPORATE DIRECTORY Indicative Timetable Rights Issue Timetable Lodgment of Prospectus with ASIC and Announcement to ASX .
    [Show full text]
  • Drug Delivery Technology Y
    * DDT Nov-Dec 2007 Working 11/9/07 2:29 PM Page 1 November/December 2007 Vol 7 No 10 IN THIS ISSUE Company Profiles 12 Drug Delivery Technologies 58 Excipients, Polymers, Liposomes & Lipids 78 Contract Pharmaceutical & Biological Development Services 83 Machinery & Laboratory Equipment and Software 96 Technology Showcase 102 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2007 Working 11/9/07 2:39 PM Page 2 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 3 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 4 November/December 2007 Vol 7 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Coming in 2008 Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Drug Delivery Weekly & Fax: (703) 548-3733 E-mail: [email protected] Specialty Pharma News E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] 0 The weekly electronic newsletter from the publishers of Drug 1 International o N Delivery Technology and Specialty Pharma will provide over 12,000 Ralph Vitaro 7 219 Changebridge Road l o subscribers with the latest news of business deals, alliances, and V Montville, NJ 07045 Tel: (973) 299-1200 7 technology breakthroughs from the pharmaceutical, specialty 0 Fax: (973) 299-7937 0 2 pharmaceutical, drug delivery, and biotechnology industries.
    [Show full text]
  • Market Insight – August 2015 Welcome to “The Baader-Meinhof Phenomena”… by Jon Michel
    SYDNEY MELBOURNE Level 24 Level 5 400 George Street 189 Flinders Lane SYDNEY NSW 2000 MELBOURNE VIC 3000 Tel 61 2 9235 9400 Tel 61 3 9653 8600 Market Insight – August 2015 Welcome to “The Baader-Meinhof Phenomena”… By Jon Michel I recently had the pleasure of working on a really interesting role for one of our clients. Having presented a particularly cracking shortlist, I noticed that three of the top four candidates had ended up on our shores in similar circumstances. They (guys) were all here as a result of meeting and marrying Australian girls who had been travelling overseas… think Contiki tours got a mention at least once! Each couple had initially settled and had children abroad (Europe/US) and then, largely due to those Aussie girls wanting to be closer to family and bring up the kids here, they had relocated to Australia. Put it this way, the move was not driven by career priorities but instead by family and lifestyle considerations. Anyway, since that shortlist construction, I seem to keep bumping into people who have ended up here through the same scenario. Now, I’d always called this the ‘Pink VW’ syndrome: i.e. you see one pink Volkswagen, then as it sits in the forefront of your consciousness, you continually seem to register them as you go. Well, it does exist but it’s actually called the Baader-Meinhof phenomena. Seriously, Google it. A bizarre choice, referencing it to an urban German terrorist gang of the 1970’s... go figure. Apart from you now being prepared when this topic inevitably comes up in your next Trivial Pursuit quiz, I also wanted to highlight the excellent talent pool that us recruiters get to tap into as a result of such offshore unions and subsequent relocations down under.
    [Show full text]
  • Progress Report January 2009 – December 2011
    North Carolina State University Professional Science Master’s Program Progress Report January 2009 – December 2011 The Graduate School College of Agriculture & Life Sciences College of Design College of Education College of Engineering College of Humanities & Social Sciences Poole College of Management College of Natural Resources College of Physical & Mathematical Sciences College of Textiles College of Veterinary Medicine First-Year College 1 Greetings From the UNC System PSM Director The Professional Science Master’s (PSM) Program is one of the University of North Carolina (UNC) System’s ways to close the existing skills gap in the workplace. Together with local employers, we design graduate education and training regimens to match employers’ needs. The UNC System has undertaken a collaborative effort to develop these new programs in key areas of importance to North Carolina’s local economies. I am pleased to report that NC State University now offers nine PSM programs. Several new programs are at various planning stages, and numerous new central resources and services are available or under way for these programs. A special milestone in 2010 was the establishment of the PSM Council at NC State University. Members of this group include faculty who direct PSM programs or are planning to offer them in the future. The PSM Council oversees new program development and determines the future strategy for the PSM programs at NC State University. Another important milestone was the award of a new UNC System grant from the Alfred P. Sloan Foundation and support from the UNC General Administration for multiple online tools. I am greatly indebted to the many employers, professors and students who contribute to the collective success of NC State University’s PSM programs.
    [Show full text]
  • BBY Client Monies Investigation Report: 22 December 2015
    + BBY Limited (Receivers and Managers Appointed) (In Liquidation) ACN 006 707 777 Client monies investigations Liquidators’ Report Stephen Vaughan and Ian Hall Joint and Several Liquidators KPMG 10 Shelley Street Sydney 22 December 2015 2 © 2015 KPMG, an Australian partnership and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved. The KPMG name, logo and "cutting through complexity" are registered trademarks or trademarks of KPMG International. Liability limited by a scheme approved under Professional Standards Legislation. Glossary ABN ABN Amro, Futures clearing house AC Account Number ACN Australian Company Number Act Corporations Act 2001 (Cth) ACH ASX Clearing House ADM ADM Investor Services International Administrators Stephen Vaughan and Ian Hall of KPMG AFSL Australian Financial Services Licence AIMS AIMS Financial Group Agility Agility Applications Pty Ltd ANZ Australia and New Zealand Banking Group APX Asia Pacific Stock Exchange AQA Aquila Resources Limited ARITA Australian Restructuring, Insolvency and Turnaround Association ARCC Audit, Risk and Compliance Committee ASIC Australian Securities and Investments Commission ASX Australia Stock Exchange ATO Australian Taxation Office BAU Business as Usual BBO Business Banking Online BBYAS BBY Advisory Services Pty Ltd BBYH BBY Holdings BBYHT BBY Hometrader Pty Ltd BBYN BBY Nominees Pty Ltd BBYPN BBY Protection Nominees Pty Ltd BBY Companies BBY Limited and each of
    [Show full text]
  • PIIS0016508516348168(1).Pdf
    Gastroenterology 2016;151:651–659 CLINICAL—LIVER High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis Edward Gane,1 Fred Poordad,2 Stanley Wang,3 Armen Asatryan,3 Paul Y. Kwo,4 Jacob Lalezari,5 David L. Wyles,6 Tarek Hassanein,7 Humberto Aguilar,8 Benedict Maliakkal,9 Ran Liu,3 Chih-Wei Lin,3 Teresa I. Ng,3 Jens Kort,3 and Federico J. Mensa3 1University of Auckland, Auckland, New Zealand; 2Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas; 3AbbVie, Inc, North Chicago, Illinois; 4Indiana University School of Medicine, Indianapolis, Indiana; 5Quest Clinical Research, San Francisco, California; 6University of California San Diego, La Jolla, California; 7Southern California GI and Liver Centers and Southern California Research Center, Coronado, California; 8Louisiana Research Center, Shreveport, Louisiana; 9University of Rochester Medical Center, Rochester, New York to liver decompensation, as defined by ascites, jaundice, See Covering the Cover synopsis on page 571; encephalopathy, or variceal bleeding.2 Achievement of a CLINICAL LIVER see editorial on page 587. sustained virologic response (SVR) reduces the risk of hepatic decompensation events, end-stage liver disease, 3–5 BACKGROUND & AIMS: The combination of ABT-493 (NS3/4A hepatocellular carcinoma, and liver-related mortality. protease inhibitor) plus ABT-530 (NS5A inhibitor) has shown Recognizing the need to prevent these complications, the high rates of sustained virologic response at post-treatment American Association for the study of Liver Diseases/ week 12 (SVR12) in noncirrhotic patients infected with hepa- Infectious Disease Society of America, and the European titis C virus (HCV) genotypes (GTs) 1–6.
    [Show full text]
  • Radius Health, Inc
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 RADIUS HEALTH, INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ Fee paid previously with preliminary materials: ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount previously paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: April 20, 2018 To Our Stockholders: You are cordially invited to attend the 2018 Annual Meeting of Stockholders of Radius Health, Inc.
    [Show full text]
  • (R&D) Tax Credit
    Report toThe the Pennsylvania Pennsylvania Department of General Revenue Assembly Bureau of Research on the Research and Development (R&D) Tax Credit The Pennsylvania Department of Revenue Bureau of Research March 15, 2012 Pennsylvania Research and Development Tax Credit Page 1 of 14 The Pennsylvania R&D Tax Credit Statute On May 7, 1997, Act 7 of 1997 created the Pennsylvania research and development (R&D) tax credit. The R&D tax credit provision became Article XVII-B of the Tax Reform Code of 1971 (TRC). The intent of the R&D tax credit was to encourage taxpayers to increase R&D expenditures within the Commonwealth in order to enhance economic growth. The terms and concepts used in the calculation of the Commonwealth’s R&D tax credit are based on the federal government’s R&D tax credit definitions for qualified research expense.1 For R&D tax credits awarded between December 1997 and December 2003, Act 7 of 1997 authorized the Department of Revenue (Department) to approve up to $15 million in total tax credits per fiscal year. Additionally, $3 million of the $15 million was set aside for “small” businesses, where a “small business” is defined as a “for-profit corporation, limited liability company, partnership or proprietorship with net book value of assets totaling…less than five million dollars ($5,000,000).” Over the years, several changes have been made to the R&D tax credit statute. Table 1 lists all of the acts that have changed the R&D tax credit statute, along with the applicable award years, the overall tax credit cap and the “small” business set aside.
    [Show full text]
  • 4Oct200722045121 1Dec200517045043
    4OCT200722045121 This prospectus (the ‘‘Prospectus’’) relates to the initial offering (the ‘‘Offering’’) to subscribe for up to A75 million of new common shares in Ablynx NV (the ‘‘Company’’ or ‘‘Ablynx’’), with VVPR strips (the ‘‘VVPR Strips’’). This amount of New Shares with VVPR Strips may be increased by up to 15 per cent, to an amount of A86.25 million (the ‘‘Increase Option’’, the new shares initially offered and the shares offered as a result of the possible exercise of the Increase Option jointly being referred to as the ‘‘New Shares’’). Any decision to exercise the Increase Option will be announced, at the latest, on the date the Offer Price is announced. JPMorgan and KBC Securities (the ‘‘Joint Global Coordinators’’) will be granted an over-allotment option by the Company (the ‘‘Over-allotment Option’’), exercisable as of the listing date (the ‘‘Listing Date’’) and until 30 days thereafter, corresponding to up to 15 per cent of the New Shares subscribed for in the Offering for the sole purpose of allowing the Joint Global Coordinators to cover over-allotments, if any. The existing shares covered by the Over-allotment Option (the ‘‘Additional Shares’’ and, together with the New Shares, the ‘‘Offered Shares’’) and the New Shares issued upon exercise of the Over-allotment Option, if any, will not have a separate VVPR Strip. The Offered Shares are offered to the public in Belgium (including to employees, consultants and independent directors of the Company in Belgium) and, pursuant to a private placement, to institutional investors, both within and outside Belgium and to employees, consultants and independent directors of the Company outside Belgium.
    [Show full text]
  • The Australian National Registry of Emissions Units
    The Australian National Registry of Emissions Units ANREU - Authorised Entities Report 13/CMP.1 Paragraph 48 Report Generated: 24/07/20 1:55:26 AM Total Number of Authorised Entities: 1122 List of Legal Entities Authorised to hold ERUs, CERs, AAUs, and/or RMUs 1st Energy Pty Ltd A. A. Company Pty. Ltd. A.B.C. Paper & Paper Mills Pty. Limited A.J. BUSH & SONS (MANUFACTURES) PTY LTD Aak Puul Ngantam Ltd. Aboriginal Carbon Fund Limited ACCU Asset Management Pty Ltd Adam John Robinson Adam Richard Nixon Adelaide Brighton Cement Limited ADELAIDE BRIGHTON MANAGEMENT LTD Adrian Lewis Schmidt Advanced Energy Centre Pty. Ltd. AEDP CARBON PTE LTD AETV PTY LTD Agasco Limited AGL ACT Retail Investments Pty Limited AGL Energy Limited AGL Energy Sales & Marketing Limited AGL Energy Services Pty Limited AGL HP1 Pty Limited AGL HP2 Pty Limited AGL HP3 Pty Limited AGL Hydro Partnership AGL Macquarie Pty Limited AGL POWER GENERATION PTY LIMITED AGL Retail Energy Limited AGL SALES (QUEENSLAND) PTY LIMITED AGL Sales Pty Limited AGL SOUTH AUSTRALIA PTY LIMITED AGL Torrens Island Pty Limited AGL Wholesale Gas Limited Agriprove Pty Ltd Agriprove Solutions Pty Ltd Alan Carl Pulsford Alan Peter Cole Alan Stuart John Lawson Albury City Council 1 ALCOA AUSTRALIA ROLLED PRODUCTS PTY LIMITED Alcoa of Australia Limited Alfa (NT) Limited Alfred James Clark ALINTA COGENERATION (PINJARRA) PTY LTD Alinta Cogeneration (Wagerup) Pty Ltd ALINTA ENERGY CEA PTY LTD ALINTA ENERGY RETAIL SALES PTY. LTD. ALINTA SALES PTY LTD Allgas Energy Pty Limited Alpine MDF Industries Pty
    [Show full text]
  • Life Sciences Industry Wake County * Research Triangle Index of Featured Organizations Contract Research Contract Manufacturer 48
    LIFE SCIENCES INDUSTRY WAKE COUNTY * RESEARCH TRIANGLE INDEX OF FEATURED ORGANIZATIONS Contract Research Contract Manufacturer 48. Kurve Technology, Inc. ...............................D4 49. LaamScience, Inc. ...............................C4, I10 1. A10 Clinical Solutions, Inc. ........................E5 71. Accurate Machine and Tool Co. .................E8 50. LipoScience, Inc. ........................................C7 2. AAIPharma, Inc....................................C4, I11 72. Better Medicines, LLC ................................C3 51. Mardil, Inc. ..................................................D4 3. Alpha-Gamma Technologies, Inc. ..............D7 73. Merck BioManufacturing Network .............D4 52. MDxHealth, Inc. ................................... B3, G9 4. Analytical Solutions, Inc. ..................... C3, H9 74. Nortech Systems 53. Med-El Corp. ..................................... B3, G10 5. Appealing Products, Inc. ............................E6 (Formally TriVirix International) ..................A3 54. MedFaxx, Inc. .............................................A8 6. BIoCI Systems, Inc. ....................................D8 75. Patheon, Inc. .......................................C4, I11 55. Medisim USA .............................................. F5 7. BioLink Life Sciences, Inc. .........................D4 76. Rockwell Automation Life Sciences ...........E4 56. Medis Medical Imaging Systems, Inc. ........C7 8. Burleson Research Technologies ..............C4 77. Stainless Steel Fabrications .......................D7
    [Show full text]
  • February 19, 2014
    CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS Oversight Committee Meeting February 19, 2014 CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS Summary Overview of the February 19, 2014, Oversight Committee Meeting Please find enclosed the meeting packet for the next meeting of the CPRIT Oversight Committee to be held on Wednesday, February 19, 2014, at 10:00 AM. This summary overview of major agenda items provides background on key issues for Committee consideration. CEO Report Wayne Roberts will present the CEO’s report and address issues assigned by the Oversight Committee at the January 24th meeting including reconstituting the University Advisory Committee (UAC) and proposed dashboard metrics for the agency. Chief Scientific Officer Program Portfolio Presentation and Grant Award Recommendations Dr. Margaret Kripke will present the Program Integration Committee’s recommendations for scientific research awards. The research continuation grant recommendations are the first grant applications to be considered under the “new” review process set out by SB 149. SB 149 changed the way that grant recommendations are formally approved. A vote by two-thirds of the Oversight Committee that are present and voting (i.e. not recused because of a conflict of interest) is required to approve each funding recommendation. If two-thirds of the Oversight Committee does not vote to approve an award recommendation, then a statement explaining the reason for not following the PIC’s recommendation must be included in the meeting minutes. Product Development Officer Program Portfolio Presentation and Grant Award Recommendations Kristen Doyle, acting Product Development Officer, and Dr. Jack Geltosky, CPRIT’s Product Development Review Council Chair, will discuss CPRIT’s product development portfolio and present the Chief Executive Officer’s recommendations for product development grant awards.
    [Show full text]